Find Academic Supervisors

Robert Wilson is an Associate Professor in the School of Psychology at Georgia Institute of Technology. His research focuses on computational cognitive neuroscience, reinforcement learning, decision making, and their applications in psychiatry and aging. Wilson leads a lab integrating computational modeling with behavioral experiments, neuroimaging, and neurostimulation to explore the algorithms underlying human cognition. He holds a Ph.D. in Bioengineering from the University of Pennsylvania (2009). Education: Ph.D. in Bioengineering, University of Pennsylvania, 2009 Research Interests: Wilson’s work spans computational models of decision making, reinforcement learning dynamics, and the neural mechanisms of explore-exploit trade-offs. His lab investigates phishing detection cognition, navigation strategies, and perceptual decision making, with recent studies on aging-related cognitive decline and psychiatric disorders. Publications: His recent work includes studies on computational models of exploration strategies, phishing susceptibility (PEST task), and aging effects on decision-making. Articles often bridge neuroscience and AI, such as applying reinforcement learning to large language models. Awards & Grants: While no formal awards are listed, his research has been supported by grants exploring computational psychiatry and neuroimaging. Labs & Teams: Wilson directs a multidisciplinary lab at Georgia Tech, collaborating with experts in AI, neuroscience, and clinical psychology to advance computational theories of the mind-brain relationship.

• Computational Cognitive Neuroscience
• Reinforcement Learning
• Decision Making
• +7 more

Bernadka Dubicka is a Clinical Professor and Honorary Clinical Chair in the Division of Neuroscience at the University of Manchester. She holds dual roles as a research lead at Pennine Care NHS Foundation Trust and as the child and adolescent mental health research lead for Health Innovation Manchester. She is the Editor-in-Chief of the Journal of Child and Adolescent Mental Health and previously served as Chair of the Child and Adolescent Faculty at the Royal College of Psychiatrists (2017–2021). Her academic qualifications include a BSc in Psychology and MBBs from University College London, followed by FRCPsych accreditation in child psychiatry. She earned a gold medal for her MD thesis on behavioral disorder implications in depression. Dubicka’s research focuses on adolescent depression, mood disorders, and brief interventions, including the IMPACT and STADIA trials evaluating psychological treatments and standardized diagnostic assessments. Her work also addresses technology’s role in youth mental health and the eco-crisis’s mental health impacts. Education: BSc Psychology, University College London MBBs, University of London MD Thesis (Gold Medal), University College London FRCPsych, Royal College of Psychiatrists Her research spans depression treatment efficacy, behavioral activation, and cross-national studies on pediatric bipolar disorder. She collaborates internationally and has led over 49 publications. Awards include a gold medal for her thesis and recognition as an RCPsych Fellow. Her work also emphasizes policy advocacy, such as addressing digital rights for children and mental health responses to climate change (e.g., COP26 contributions). She trains clinicians in brief psychosocial interventions and behavioral activation through academic programs and national courses. Grants & Funding: Co-investigator on the £1.1M HTA-funded STADIA trial evaluating remote mental health assessments. Principal investigator on the IMPACT trial, one of the largest adolescent depression trials globally. Labs/Teams: Collaborations include the University of Cambridge (IMPACT trial), University of Nottingham (STADIA), and international taskforces on treatment-resistant depression.

• Mood Disorders
• Adolescent Mental Health
• Depression Treatment
• +3 more

John D. Murray is the Gregg L. Engles Associate Professor of Psychological and Brain Sciences at Dartmouth College and an Adjunct Associate Professor of Psychiatry at Yale School of Medicine. He holds a PhD in Physics from Yale University (2013) and a BS in Physics and Mathematics from Yale (2006). His research focuses on computational neuroscience and computational psychiatry, with secondary appointments in Physics and Neuroscience at Yale until 2023. His work integrates computational modeling, neuroimaging, and systems neuroscience to study decision-making processes, cortical organization, and psychiatric disorders. Collaborators include prominent researchers like Dr. John Krystal and Dr. Anticevic. Research interests include hierarchical brain organization, neuroimaging analysis techniques, and pharmacological effects on neural circuits. His lab (Murray Lab) develops computational tools like PsychRNN for cognitive task modeling. Notable contributions include linking transcriptomic data to neuroimaging patterns and modeling LSD’s effects on brain topography. He has been featured in YaleNews and Nature Communications for innovations in mapping mental illness variability and neural circuit dynamics. Grants and collaborations span translational neuroscience, addiction, and PTSD research through partnerships with Yale’s Center for Biomedical Data Science and VA National Center for PTSD. His interdisciplinary approach bridges physics, computer science, and clinical psychiatry to advance understanding of brain function and dysfunction.

• Computational Neuroscience
• Computational Psychiatry
• Neuroimaging
• +3 more

Ashli Owen-Smith is a behavioral scientist affiliated with the School of Public Health at Georgia State University , where her research focuses on mental health disparities, suicide prevention, and integrative/complementary approaches for complex mental-physical health conditions. She works with underserved populations including refugees/immigrants, incarcerated individuals, and LGBTQ+ communities through community-based participatory research and mixed-methods frameworks. Her current projects are funded by CDC , DBHDD , and DPH . Education: Ph.D. in Behavioral Sciences (Emory, 2009), S.M. in Public Health (Harvard, 2005), B.A. in Psychology (Smith College, 2001) Her research spans mental health , trauma , suicide prevention , and mindfulness-based interventions . Recent work examines telehealth adaptations for chronic pain and mental health, vaccine hesitancy in refugee communities, and social determinants of suicide . She leads studies on gender-affirming care and health disparities in LGBTQ+ populations. Key article trends include epidemiological analysis of suicide risk factors, COVID-19 impacts on mental health, ICD-10 coding for autism, and complementary medicine in trauma recovery. Subfields span telehealth , health equity , mental-physical comorbidity , and community engagement . Students she has mentored include C.A. Scarlett , T. Griner , and M.M. Sesay . Her work integrates public health policy , clinical research , and health systems analysis .

• Mental Health
• Behavioral Science
• Trauma
• +6 more

Univ-Prof. Dr. med. Malek Bajbouj serves as Director of the Institute for Affective Neuroscience and Emotion Modulation at Charité – University Medicine Berlin's Campus Benjamin Franklin (CBF), operating within the Department of Neurology, Neurosurgery and Psychiatry (CC 15). His position integrates clinical leadership with translational neuroscience research focused on severe mental illnesses. Dr. Bajbouj's research program centers on affective neuroscience and emotion dysregulation mechanisms in psychiatric disorders, particularly schizophrenia spectrum conditions and depression. He pioneers multimodal intervention approaches combining neuromodulation (tDCS), oxytocin augmentation, mindfulness therapies, and digital health tools. His work emphasizes translational biomarker development using neuroimaging, machine learning, and physiological stress parameter analysis to personalize treatment for treatment-resistant populations. Analysis of his 2023-2025 publications reveals three dominant research trajectories: (1) novel treatment combinations for negative symptoms in schizophrenia (oxytocin + mindfulness, yoga therapy); (2) real-world implementation of neuromodulation (at-home tDCS protocols, technical efficacy monitoring); and (3) global mental health responses to crises (pandemic impacts on vulnerable groups, culturally adapted refugee interventions). His methodology consistently employs rigorous randomized controlled trials with embedded biomarker studies. As director of his eponymous institute, Dr. Bajbouj leads a multidisciplinary team conducting neuroimaging studies, clinical trials, and international collaborations focused on emotion modulation pathways. The institute coordinates research across CC 15's clinical infrastructure at CBF Building V, with particular emphasis on bridging laboratory neuroscience with clinical psychiatry through the DepressionDC and OXYMIND trial frameworks.

• Affective Neuroscience
• Emotion Regulation
• Schizophrenia Spectrum Disorders
• +4 more

Michael J. Frank is the Edgar L. Marston Professor of Psychology and Professor of Brain Science at Brown University's School of Cognitive, Linguistic, and Psychological Sciences. He holds academic affiliations with the Carney Institute for Brain Science and specializes in cognitive neuroscience, computational neuroscience, and decision-making processes. Frank earned his Ph.D. in Neuroscience & Psychology from the University of Colorado at Boulder in 2004, and joined Brown University in 2011 after serving as a Professor at the University of Arizona. His research integrates computational modeling and experimental methods to explore neural mechanisms underlying reinforcement learning, decision-making, and cognitive control, with a focus on prefrontal cortex-basal ganglia interactions and dopamine modulation. Frank's honors include the Troland Research Award (2021), Kavli Fellowship (2016), and the Cognitive Neuroscience Society Young Investigator Award (2011). He is an editor for eLife, Behavioral Neuroscience, and the Journal of Neuroscience. His lab, based at http://ski.clps.brown.edu, investigates topics such as neural circuit models of cognitive control, neuropsychological testing, and translational applications of computational models in psychiatry. Frank's research emphasizes interdisciplinary approaches, combining behavioral experiments, neuroimaging (fMRI, EEG), and pharmacological studies to dissect brain-behavior relationships. Key findings include insights into dopamine's role in motivation, decision-making deficits in schizophrenia, and computational phenotyping of mental disorders. His work bridges basic science and clinical applications, aiming to inform therapeutic strategies for neurological and psychiatric conditions.

• Cognitive Neuroscience
• Computational Neuroscience
• Decision Making
• +3 more

Dr. Camilla Nord serves as Assistant Professor of Cognitive Neuroscience at the University of Cambridge's Department of Psychiatry and is Programme Leader at the MRC Cognition and Brain Sciences Unit. She holds dual appointments as Co-Director of Postgraduate Education & Director of the MPhil in Cognitive Neuroscience at the MRC CBU, and as Fellow and Director of Studies at Christ's College Cambridge. Nord directs the Mental Health Neuroscience Lab (nordlab.co.uk), which focuses on translating neuroscience into improved mental health treatments through innovative pharmacological, psychological, and neurostimulation interventions. Her research spans three interconnected streams: Discovery Science investigates brain-body interactions including interoception, circadian rhythms, and metabolism as neglected sources of mental health information; Experimental Medicine employs pharmacological manipulation, brain stimulation, and psychological interventions to establish causal relationships between physiological mechanisms and mental health conditions; and Translational Neuroscience develops clinical trials for neuroscience-based interventions, particularly 'acute augmentations' that enhance psychological therapy efficacy. Her lab has demonstrated how gut states cause disgust avoidance and how psychological therapy techniques alter negative learning processes. Analysis of Nord's publication record reveals a strong emphasis on computational approaches to mental health, with particular focus on depression treatment mechanisms. Her work increasingly integrates brain-body interactions, especially gut-brain and metabolic pathways, into mental health frameworks. Recent publications show growing emphasis on patient-centered research, interoception, and transdiagnostic approaches that cut across traditional psychiatric categories. Wellcome Career Development Award (£1.5 million) Wellcome Mental Health Award (£4.3 million, jointly awarded with Prof. Sarah Garfinkel) Sunday Times Book of the Year (2023) for 'The Balanced Brain: The Science of Mental Health' Financial Times Book of the Year (2023) for 'The Balanced Brain: The Science of Mental Health' Nord actively mentors PhD students and postdoctoral researchers, with her trainees receiving prestigious awards including the British Association of Psychopharmacology (BAP) Poster Prize, BAP Hannah Steinberg Bursary, and Alwyn Lishman Prize. Her lab is currently funded by MRC intramural funding, a Wellcome Career Development Award, and a Wellcome Mental Health Award, supporting innovative research at the intersection of neuroscience and mental health treatment. The Mental Health Neuroscience Lab operates within the MRC Cognition and Brain Sciences Unit, collaborating extensively with researchers across Cambridge and internationally. The lab maintains strong connections with clinical services and patient groups, ensuring research remains grounded in real-world mental health challenges. Current work focuses on transcranial ultrasound stimulation, gut-brain axis interventions, and computational modeling of mental health mechanisms.

• Computational Psychiatry
• Cognitive Neuroscience
• Psychopharmacology
• +7 more

Eileen Klein is an Associate Professor of Social Work and Convener of the BSW Program at Ramapo College of New Jersey's School of Social Science and Human Services. Her work focuses on LGBTQ mental health treatment , community support systems , and policy reform for marginalized populations. Klein has presented extensively at international conferences on topics like cultural competency in social work education and LGBTQ health disparities . Ph.D., M.S., and M.S.W. from New York University and SUNY Buffalo Key research areas: LGBTQ Mental Health, Community Health Disparities, Forensic Social Work Published 15+ works (2013-2021) on topics ranging from polypharmacy to support programs for LGBTQ clients Active in professional development: Delivered presentations at conferences across the U.S. and Italy on topics including integrated treatment and supervision of student interns

• Community Mental Health
• LGBTQ Mental Health Treatment
• Social Work Policy Advocacy
• +3 more

Dr. Kenji Fujita is a Research Fellow at the Kolling Institute, University of Sydney, specializing in ageing, pharmacology, and pharmaceutical care quality. He holds a PhD, MScMed (ClinEpid), and BPharm from the University of Sydney. Previously a pharmacist in Japan, he leads international initiatives in the Pharmaceutical Care Network Europe (PCNE) and the International Pharmaceutical Federation (FIP). His work focuses on deprescribing strategies, polypharmacy, and developing quality indicators for healthcare services. Dr. Fujita’s research integrates big data analysis, statistical modeling, and machine learning to address challenges in geriatric pharmacotherapy. Current projects include validating frailty indices, evaluating deprescribing interventions in older adults, and developing NLP tools for clinical documentation analysis. He has also contributed to assessing organizational readiness for guideline implementation in community pharmacies. Awards include the 2023 Outstanding Poster Presentation Award at the IAGG Asia/Oceania Congress and 2022 Best Poster at the Japanese Society of Social Pharmacy. He has secured grants such as the 2024 electronic frailty index project and the 2021 systems-approach to medication review initiative. Dr. Fujita collaborates with global networks like J-HOP (Japan Home Visiting Pharmacy Association) and leads multidisciplinary teams across Australia and Europe. His lab focuses on translating data-driven insights into actionable clinical practices to improve medication safety and quality in ageing populations.

• Healthy Ageing
• Pharmacology
• Pharmacoepidemiology
• +3 more

Dr. Lauren Cirrincione is an Associate Professor in the Department of Pharmacy at the University of Washington School of Pharmacy in Seattle, Washington. Her academic appointment is within the Department of Pharmacy, which is part of the School of Pharmacy at the University of Washington. Dr. Cirrincione earned her Doctor of Pharmacy (PharmD) degree from the University of Pittsburgh School of Pharmacy and a Master of Public Health (MPH) in epidemiology from the University of Nebraska Medical Center. She completed a clinical pharmacology fellowship in HIV at the University of Nebraska Medical Center. Dr. Cirrincione's research program addresses mechanisms of hormone-mediated drug interactions, with a primary focus on clinical, translational pharmacology in transgender medicine. Her expertise spans Infectious Diseases, Mechanisms of Drug Interactions, Pharmacokinetics-Pharmacodynamics, Transgender and Gender Diverse Research, and Translational Research. Her work examines how gender-affirming hormone therapy interacts with other medications, particularly antiretrovirals, and investigates the clinical implications of these interactions for transgender patients. She has made significant contributions to understanding estradiol concentrations in gender-affirming therapy, kidney function assessment in gender-diverse populations, and the inclusion of transgender individuals in clinical trials. Her publications demonstrate a consistent focus on improving pharmacological care for transgender and gender-diverse individuals, with recent work examining adolescent transgender medicine, psychotropic medication interactions, and self-injection experiences among transgender people on hormone therapy. Her research bridges clinical pharmacology with gender-affirming care, addressing critical gaps in evidence-based practice for this population. Dr. Cirrincione teaches PHRMCY 535: Pharmacotherapeutics V at the University of Washington School of Pharmacy. Her scientific contributions have advanced the field of transgender pharmacology, with particular emphasis on clinical applications and evidence-based approaches to medication management for transgender patients.

• Infectious Diseases
• Mechanisms of Drug Interactions
• Pharmacokinetics-Pharmacodynamics
• +5 more

Markus Heilig is a Professor of Psychiatry and Head of the Department of Biomedical and Clinical Sciences (BKV) at Linköping University. He serves as Director of the Center for Social and Affective Neuroscience (CSAN), integrating basic and clinical neuroscience to address addictive and affective disorders. His work bridges neuropharmacology, molecular psychiatry, and clinical trials. Linköping University (Current) Center for Social and Affective Neuroscience (CSAN) (Director) Wallenberg Center for Molecular Medicine (Collaborator) His research focuses on alcohol dependence mechanisms, stress-neurotransmitter interactions (e.g., CRF, substance P, endocannabinoids), and personalized medicine approaches. Using animal models and human neuroimaging (fMRI), his lab explores epigenetic changes in frontal lobe and amygdala neurons that drive compulsive alcohol use. Recent publications highlight his work on endocannabinoid modulation for PTSD treatment, neural correlates of reward choices, and pharmacological interventions targeting GABA and opioid receptors. His studies often combine brain imaging, behavioral analysis, and pharmacology. Scientific awards include the 2019 Wallenberg Clinical Scholar grant and 2017 CAN/Nordic Drugs prizes. Heilig's research is supported by Vetenskapsrådet (SEK 57 million center funding) and international donations like the Andrew J. Bock Memorial Fund.

• Addiction Neuroscience
• Alcohol Dependence
• Neuropharmacology
• +4 more

Philip Burnet is a Professor of Neuroscience at the University of Oxford, affiliated with the Department of Psychiatry . He serves as the Director of Graduate Studies for Psychiatry , teaches on the MSc Neuroscience and MRCPsych courses, and sits on the editorial board of Nutrition and Aging . His research bridges neuroscience and psychiatry, focusing on neurotransmitter modulation and brain health. Research interests: Burnet investigates the regulation of serotonin and glutamic acid systems in aging and psychiatric disorders. Key projects include exploring D-amino acid oxidase (DAO) inhibition to restore cognition in schizophrenia, analyzing the microbiome-gut-brain axis , and testing dietary interventions like probiotics and ketogenic diets for mental health applications. His work combines molecular techniques with behavioral studies in preclinical and clinical contexts. Article trends reveal a focus on neurotransmitter dynamics , microbiome-brain interactions , and metabolic interventions . Notable methods include RNA interference , animal models , and clinical trial protocols . Professional activities: Collaborates across Oxford and with industry partners, contributes to academic editing, and engages in graduate education leadership.

• Neuroscience
• Psychiatry
• Neurotransmitter Modulation
• +5 more

Jonathan L. Rogers is a Professor in the Accounting Department at Leeds School of Business, University of Colorado Boulder. He maintains his office in Koelbel Building, room 433, and can be contacted at jonathan.rogers@colorado.edu or by phone at 303-735-6620. Dr. Rogers received dual bachelor's degrees from the University of Texas in 1996: one in Business Administration with a focus in finance, and another in Economics with a minor in accounting. He earned his PhD in Accounting from the Wharton School of the University of Pennsylvania in 2005. He is also a certified management accountant and certified in financial management, though both certifications are currently inactive. Dr. Rogers' research focuses on voluntary disclosure, market microstructure, multinational firms, insider trading, and stock return volatility . His work has been published in all three top accounting journals (Journal of Accounting Research, Journal of Accounting and Economics, The Accounting Review) and has received significant attention from major media outlets including The Wall Street Journal, The New York Times, Financial Times, Fortune, Reuters, Bloomberg TV, and CNBC. His research has also been cited by members of Congress. His recent publications span a diverse range of topics from accounting and finance to meteorology and healthcare, reflecting interdisciplinary collaborations. Major themes in his work include financial disclosure practices, market microstructure, insider trading, and the dissemination of financial information. His research on SEC dissemination in high-frequency trading environments has been particularly influential in both academic and regulatory circles. 2015 EKS&H Faculty Fellowship 2015 RAST Conference Best Paper Award 2011 Fama-Miller Center Research Grant 2010 William Ladany Faculty Scholar 2009 Ernest R. Wish Award 2009 Initiative on Global Markets Research Grant 2003 Deloitte Foundation Doctoral Fellowship European Accounting Association's 2003 Doctoral Colloquium Fellowship 2001 Geewax, Terker & Company Prize for Investment Research Dr. Rogers serves on the editorial board of the Journal of Accounting Research and works as an ad hoc reviewer for the Journal of Finance, the Accounting Review, the Journal of Accounting and Economics, the Review of Accounting Studies, Contemporary Accounting Research, American Accounting Association Midyear, and the Annual and FARS section meetings. His research has been supported by numerous grants including those from the Fama-Miller Center, Initiative on Global Markets, and the Deloitte Foundation. While specific information about his laboratory or research team is not provided in the available text, his extensive publication record and editorial roles suggest he likely collaborates with multiple researchers and potentially supervises graduate students in accounting research.

• Accounting
• Voluntary Disclosure
• Market Microstructure
• +3 more

Ana Adan Puig is a University Professor in the Department of Clinical Psychology and Psychobiology at the University of Barcelona's Faculty of Psychology. She serves as Academic Secretary of her department and is a member of the Board of Directors of the Institute of Neurosciences of the University of Barcelona (UBNEURO). Her research focuses on psychobiology, neuropsychology, and dual disorders (comorbid mental illness and substance use disorders), with emphasis on circadian rhythms, clinical outcomes, and neurobiological mechanisms. Education: Holds dual bachelor's degrees in Psychology from the Autonomous University of Barcelona (1986) and University of Barcelona (1988), followed by a doctoral degree in Psychology from the University of Barcelona (1995). Teaching: Over the past five years has taught courses including Psychopharmacology, Neurophysiology, Neuropsychology of Development and Dementias, and Sleep Disorders at the University of Barcelona. Research Projects: Lead investigator (IP) of the 2016-2019 PSI2015-65026-P project on Psychobiology of Dual Disorders. Collaborated in several initiatives including the DIANA project studying pandemic mental health impacts. Doctoral Supervision: Advised four PhD candidates whose research addressed topics like personality profiles in dual diagnosis patients, circadian rhythm influences in addiction treatment, and neurocognitive performance in dual disorder patients. Publications: Over 30 indexed articles focusing on schizophrenia-spectrum disorders, substance use comorbidity, circadian rhythm dysregulation, and mental health outcomes.

• Psychobiology
• Neuropsychology
• Clinical Psychology
• +9 more

Dr. Donald Addington serves as a Clinical Professor in the Department of Psychiatry at the University of Calgary's Cumming School of Medicine, with full memberships at the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education. His academic career spans over 50 years, focusing on transforming mental health service delivery for schizophrenia and early psychosis through evidence-based tools and standards. His educational credentials include: MBBS in Medicine, University of London (1972) MRCPsych in Psychiatry, Royal College of Psychiatrists (1976) FRCPC in Psychiatry, Royal College of Physicians and Surgeons of Canada (1982) Dr. Addington's research integrates clinical psychiatry with health services evaluation to develop practical measurement systems. He pioneered internationally adopted instruments including depression assessment scales for schizophrenia and fidelity metrics for psychosis services, creating bridges between clinical practice, policy development, and funding mechanisms. His work establishes standardized approaches for evaluating mental health service accessibility, quality, and outcomes across diverse healthcare systems. His publication trajectory reveals consistent innovation in measurement science, evolving from the foundational Calgary Depression Scale (1990) to contemporary fidelity scales for early psychosis intervention (FEPS-FS/CHRP-FS). These works establish global benchmarks for service quality assessment, with applications spanning clinical practice guidelines, performance measurement, and cross-system outcome comparison through initiatives like the ICHOM Psychotic Disorders standard set. Dr. Addington's scientific recognition includes: Excellence in Clinical Teaching, PAIRA (1996) Leadership Award, Canadian Alliance on Mental Illness and Mental Health (2000) Gold Medal, Canadian College of Neuropsychopharmacology (2004) Michael Smith Award for Schizophrenia (2006) C.A. Roberts Award for Clinical Leadership (2011) Angelo Cocchi Award for Fidelity Implementation (2016) President’s Commendation, Canadian Psychiatric Association (2022) Dr. John M. Cleghorn Memorial Award (2024) He has secured major research funding from the National Institutes of Health, Canadian Institutes of Health Research, and Alberta Heritage Foundation for Medical Research. His leadership extends through 11 years as Department Chair of Psychiatry and two terms as Canadian Psychiatric Association Board Chair, mentoring generations of clinicians while developing tools implemented across Canadian provinces, US states, and European nations. Dr. Addington leads cross-institutional teams including the ICHOM Psychotic Disorders working group and large-scale implementation projects in Ontario, 32 US states, Czechia, and Italy. His current initiatives expand the FEPS-FS framework to clinical high-risk populations and bipolar disorder services while advancing patient-reported outcome measures for international service comparison.

• Schizophrenia Research
• Early Psychosis Intervention
• Mental Health Services Research
• +5 more